EyePoint Pharmaceuticals, Inc. — Director's Dealing 2019

Jun 12, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2019-06-10

Reporting Person: Jones David Scott (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-10	Stock Options (Right to buy)	$1.47	A	350000.00	Acquired	2029-06-10	Common Stock (350000.00)	Direct

Footnotes

F1: The option to purchase will vest and become exercisable as follows: 25% at June 10th, 2020 and the remainder ratably, on a monthly basis, over the remaining three years.